|
시장보고서
상품코드
1383107
세계의 인공눈물 시장 예측(-2030년)Artificial Tears Forecast till 2030 |
||||||
세계 인공눈물 시장은 안구건조증과 안구 염증의 유행, 무첨가 제품에 대한 선호도 증가로 인해 성장세를 보이고 있습니다.
지역별 인사이트
북미 시장은 안구건조증 확산과 시장 진입 기업의 존재로 인해 가장 큰 시장 규모를 차지했습니다. 미국에서는 안구건조증이 매우 광범위하게 퍼져 있으며, 특히 50세 이상 인구의 대다수에게 영향을 미치고 있습니다.
유럽 시장은 안과 질환의 유행, 첨단 안약의 사용 확대, 급속한 인구 증가로 인해 세계 2위의 시장으로 부상했습니다.
아시아태평양 시장은 조사 기간 동안 빠른 속도로 성장할 것으로 예상됩니다. 중국 시장이 가장 큰 시장 규모를 가지고 있으며, 인도 시장이 아시아태평양에서 가장 빠르게 성장할 것입니다.
이 보고서는 세계 인공눈물 시장을 조사 분석하여 시장 역학, 지역 및 부문 분석, 기업 개요 등을 제공합니다.
목차
제1장 주요 요약
제2장 시장 서론
제3장 조사 방법
제4장 시장 역학
- 개요
- 성장 촉진요인
- 안구건조증과 눈 염증 유행
- 보존료를 포함하지 않는 제품에 대한 관심 상승
- 성장 억제요인
- 부작용과 알레르기 반응
- 기회
- 안구건조증 진단 진보
제5장 시장 요인 분석
- 밸류체인 분석
- 연구개발
- 제조
- 유통과 판매
- 판매후 모니터링
- Porter's Five Forces 분석 모델
- 인공눈물 시장에 대한 COVID-19의 영향
- 공급망에 대한 영향
- 제조업체에 대한 영향
- 가격 분석
제6장 세계의 인공눈물 시장 : 유형별
- 개요
- 폴리에틸렌 글리콜
- 프로필렌 글리콜
- 셀룰로오스
- 글리세린
- 기타
제7장 세계의 인공눈물 시장 : 딜리버리 방식별
- 개요
- 점안약
- 연고
- 스프레이
제8장 세계의 인공눈물 시장 : 용도별
- 개요
- 안구건조증
- 알레르기와 감염증
- 기타
제9장 세계의 인공눈물 시장 : 유통 채널별
- 개요
- 병원 약국
- 드럭스토어
- 소매 약국
- 온라인 약국
제10장 세계의 인공눈물 시장 : 지역별
- 개요
- 북미
- 미국
- 캐나다
- 유럽
- 독일
- 영국
- 프랑스
- 이탈리아
- 스페인
- 기타 유럽
- 아시아태평양
- 일본
- 중국
- 인도
- 호주
- 한국
- 기타 아시아태평양
- 기타 지역
- 중동
- 아프리카
- 라틴아메리카
제11장 경쟁 상황
- 주요 발전과 성장 전략
- 제품 발매
- 제휴
- 합의
- 인수
- 파트너십
- 주요 기업 재무 매트릭스
- 판매량(2022년)
- 연구개발(2022년)
제12장 기업 개요
- JOHNSON AND JOHNSON VISION CARE
- ALLERGAN PLC
- ALCON PLC
- BAUSCH & LOMB INCORPORATED
- SANTEN, INC.
- URSAPHARM ARZNEIMITTEL GMBH
- ROHTO PHARMACEUTICAL CO., LTD.
- SIMILASAN CORPORATION
- OCUSOFT
- NICOX
제13장 부록
ksm 23.12.01Market Overview
The rising pervasiveness of dry eye infection and eye irritation, and the rising inclination for additive free items are driving market development.
The rising interest for additive free artificial tears inferable from the results of additives including eye disturbance, particularly for moderate or serious dry eyes is driving the artificial tears market. Moreover, the rising number of item dispatches by vital participants is expanding item separation and consequently driving market development. For example, In January 2022, Alcon (Switzerland) sent off Systane complete additive free oil eye drops in the European market. Similarly, in October 2019, Allergan, Inc. (Auxiliary of AbbVie, US) sent off the Invigorate Relieva grease eye drop product offering, an extension of the Revive portfolio. The product offering included Revive Relieva PF (additive free) multidose.
Moreover, expanding item dispatches for additive free items is driving the artificial tears market. Besides, propels in bundling plan and conveyance systems for additive free eye drops to forestall tainting are further driving the market for artificial tears market. Hence, expanding inclination for additive free items is driving the market development.
Market Segmentation
Based on type, the Artificial Tears Market is divided into segments such as cellulose, glycerin, propylene glycol, and polyethylene glycol. The market is separated into eye drops, ointments, and sprays based on the mechanism of delivery.
The dry eye condition, allergies, infections, and other conditions are categorized under the application sector of the artificial tears market. Hospital pharmacies, drug stores, retail pharmacies, and internet pharmacies are all part of the distribution system.
Regional Insights
The North America artificial tears market represented the largest market owing to the of the great commonness of dry eye sickness, the presence of market vital participants, and the developing interest for contact focal points in the region Dry eye illness is exceptionally far reaching in the US, influencing a huge level of the populace, especially those beyond 50 years old.
Europe artificial tears market represents the second-largest market owing to the great pervasiveness of ophthalmic issues, expanding utilization of cutting-edge eye drops, and a quickly flooding maturing populace. further, UK artificial tears market was credited to hold the biggest market share, and the France artificial tears market is supposed to quickest developing market in the European region.
The Asia-Pacific artificial tears market is supposed to develop at a fast rate during the review period. This is because of the solid likely persistent populace, rising consciousness of visual illnesses, and expanding medical services consumption in the Asia-Pacific region. Besides, China artificial tears market is supposed to hold the biggest market offer, and India artificial tears market is normal quickest developing market in the Asia-Pacific region.
Major Players
Key Companies in the worldwide Artificial Tears Market are Johnson and Johnson Vision Care (US), Allergan plc (Ireland), Alcon Plc (Switzerland), Bausch & Lomb Incorporated (Canada), Santen, Inc (Japan), URSAPHARM Arzneimittel GmbH (Germany), ROHTO Pharmaceutical CO., LTD (Japan), Similasan Corporation (US), Ocusoft (US), and Nicox (France).
TABLE OF CONTENTS
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
- 2.1 SCOPE OF THE STUDY
- 2.2 RESEARCH OBJECTIVE
- 2.3 MARKET STRUCTURE
- 2.4 ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
- 3.1 DATA MINING
- 3.2 SECONDARY RESEARCH
- 3.3 PRIMARY RESEARCH
- 3.4 BREAKDOWN OF PRIMARY RESPONDENTS
- 3.5 FORECASTING TECHNIQUES
- 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
- 3.6.1 BOTTOM-UP APPROACH
- 3.6.2 TOP-DOWN APPROACH
- 3.7 DATA TRIANGULATION
- 3.8 VALIDATION
4 MARKET DYNAMICS
- 4.1 OVERVIEW
- 4.2 DRIVERS
- 4.2.1 INCREASING PREVALENCE OF DRY EYE DISEASE AND EYE INFLAMMATION
- 4.2.2 RISING PREFERENCE FOR PRESERVATIVE-FREE PRODUCTS
- 4.3 RESTRAINTS
- 4.3.1 SIDE-EFFECTS AND ALLERGIC REACTIONS
- 4.4 OPPORTUNITIES
- 4.4.1 ADVANCEMENT IN DIAGNOSTICS FOR DRY EYE DISEASE
5 MARKET FACTOR ANALYSIS
- 5.1 VALUE CHAIN ANALYSIS
- 5.1.1 R&D
- 5.1.2 MANUFACTURING
- 5.1.3 DISTRIBUTION AND SALES
- 5.1.4 POST-SALES MONITORING
- 5.2 PORTER'S FIVE FORCES MODEL
- 5.2.1 THREAT OF NEW ENTRANTS
- 5.2.2 BARGAINING POWER OF SUPPLIERS
- 5.2.3 THREAT OF SUBSTITUTES
- 5.2.4 BARGAINING POWER OF BUYERS
- 5.2.5 INTENSITY OF RIVALRY
- 5.3 IMPACT OF COVID-19 ON THE ARTIFICIAL TEARS MARKET
- 5.3.1 IMPACT ON SUPPLY CHAIN
- 5.3.2 IMPACT ON MANUFACTURERS
- 5.4 PRICING ANALYSIS
6 GLOBAL ARTIFICIAL TEARS MARKET, BY TYPE
- 6.1 OVERVIEW
- 6.2 POLYETHYLENE GLYCOL
- 6.3 PROPYLENE GLYCOL
- 6.4 CELLULOSE
- 6.5 GLYCERIN
- 6.6 OTHERS
7 GLOBAL ARTIFICIAL TEARS MARKET, BY DELIVERY MODE
- 7.1 OVERVIEW
- 7.2 EYE DROPS
- 7.3 OINTMENTS
- 7.4 SPRAYS
8 GLOBAL ARTIFICIAL TEARS MARKET, BY APPLICATION
- 8.1 OVERVIEW
- 8.2 DRY EYE SYNDROME
- 8.3 ALLERGIES AND INFECTIONS
- 8.4 OTHERS
9 GLOBAL ARTIFICIAL TEARS MARKET, BY DISTRIBUTION CHANNEL
- 9.1 OVERVIEW
- 9.2 HOSPITAL PHARMACIES
- 9.3 DRUG STORES
- 9.4 RETAIL PHARMACIES
- 9.5 ONLINE PHARMACIES
10 GLOBAL ARTIFICIAL TEARS MARKET, BY REGION
- 10.1 OVERVIEW
- 10.2 NORTH AMERICA
- 10.2.1 US
- 10.2.2 CANADA
- 10.3 EUROPE
- 10.3.1 GERMANY
- 10.3.2 UK
- 10.3.3 FRANCE
- 10.3.4 ITALY
- 10.3.5 SPAIN
- 10.3.6 REST OF EUROPE
- 10.4 ASIA-PACIFIC
- 10.4.1 JAPAN
- 10.4.2 CHINA
- 10.4.3 INDIA
- 10.4.4 AUSTRALIA
- 10.4.5 SOUTH KOREA
- 10.4.6 REST OF ASIA-PACIFIC
- 10.5 REST OF THE WORLD
- 10.5.1 MIDDLE EAST
- 10.5.2 AFRICA
- 10.5.3 LATIN AMERICA
11 COMPETITIVE LANDSCAPE
- 11.7 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 11.7.1 PRODUCT LAUNCH
- 11.7.2 COLLABORATION
- 11.7.3 AGREEMENT
- 11.7.4 ACQUISITION
- 11.7.5 PARTNERSHIP
- 11.8 MAJOR PLAYERS FINANCIAL MATRIX
- 11.8.1 SALES (USD BILLION), 2022
- 11.8.2 R&D (USD BILLION), 2022
12 COMPANY PROFILES
- 12.1 JOHNSON AND JOHNSON VISION CARE
- 12.1.1 COMPANY OVERVIEW
- 12.1.2 FINANCIAL OVERVIEW
- 12.1.3 PRODUCTS OFFERED
- 12.1.4 KEY DEVELOPMENTS
- 12.1.5 SWOT ANALYSIS
- 12.1.6 KEY STRATEGIES
- 12.2 ALLERGAN PLC
- 12.2.1 COMPANY OVERVIEW
- 12.2.2 FINANCIAL OVERVIEW
- 12.2.3 PRODUCTS OFFERED
- 12.2.4 KEY DEVELOPMENTS
- 12.2.5 SWOT ANALYSIS
- 12.2.6 KEY STRATEGIES
- 12.3 ALCON PLC
- 12.3.1 COMPANY OVERVIEW
- 12.3.2 FINANCIAL OVERVIEW
- 12.3.3 PRODUCTS OFFERED
- 12.3.4 KEY DEVELOPMENTS
- 12.3.5 SWOT ANALYSIS
- 12.3.6 KEY STRATEGIES
- 12.4 BAUSCH & LOMB INCORPORATED
- 12.4.1 COMPANY OVERVIEW
- 12.4.2 FINANCIAL OVERVIEW
- 12.4.3 PRODUCTS OFFERED
- 12.4.4 KEY DEVELOPMENTS
- 12.4.5 SWOT ANALYSIS
- 12.4.6 KEY STRATEGIES
- 12.5 SANTEN, INC.
- 12.5.1 COMPANY OVERVIEW
- 12.5.2 FINANCIAL OVERVIEW
- 12.5.3 PRODUCTS OFFERED
- 12.5.4 KEY DEVELOPMENTS
- 12.5.5 SWOT ANALYSIS
- 12.5.6 KEY STRATEGIES
- 12.6 URSAPHARM ARZNEIMITTEL GMBH
- 12.6.1 COMPANY OVERVIEW
- 12.6.2 FINANCIAL OVERVIEW
- 12.6.3 PRODUCTS OFFERED
- 12.6.4 KEY DEVELOPMENTS
- 12.6.5 KEY STRATEGIES
- 12.7 ROHTO PHARMACEUTICAL CO., LTD.
- 12.7.1 COMPANY OVERVIEW
- 12.7.2 FINANCIAL OVERVIEW
- 12.7.3 PRODUCTS OFFERED
- 12.7.4 KEY DEVELOPMENTS
- 12.7.5 KEY STRATEGIES
- 12.8 SIMILASAN CORPORATION
- 12.8.1 COMPANY OVERVIEWS
- 12.8.2 FINANCIAL OVERVIEW
- 12.8.3 PRODUCTS OFFERED
- 12.8.4 KEY DEVELOPMENTS
- 12.8.5 KEY STRATEGIES
- 12.9 OCUSOFT
- 12.9.1 COMPANY OVERVIEW
- 12.9.2 FINANCIAL OVERVIEW
- 12.9.3 PRODUCTS OFFERED
- 12.9.4 KEY DEVELOPMENTS
- 12.9.5 KEY STRATEGIES
- 12.10 NICOX
- 12.10.1 COMPANY OVERVIEW
- 12.10.2 FINANCIAL OVERVIEW
- 12.10.3 PRODUCTS OFFERED
- 12.10.4 KEY DEVELOPMENTS
- 12.10.5 KEY STRATEGIES
13 APPENDIX
- 13.1 REFERENCES
- 13.2 RELATED REPORTS
